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Abstract
Rationale: Although health surveys are routinely used to
estimate the population incidence and prevalence of many
chronic and acute conditions in the U.S. population, they
have infrequently been used for “rare” conditions such as
primary immunodeficiency diseases (PID). Accurate prev-
alence measures are needed to separate the truly rare
condition from those that primary care doctors are likely
to see in their practices today, if early diagnosis and
treatment are to be achieved.
Methods: A national probability sample of 10,000 house-
holds was sampled by random digit dialing and screened by
telephone to identify how many of the nearly 27,000
household members had been diagnosed with a PID.
Results: A total of 23 household members in 18 households
were reported with a specific diagnosis for PID (CVID, IgA,
IgG, XLA, SCID, CGD), whereas additional cases were
reported as a PID without a confirmatory diagnosis. These
findings suggest a population prevalence of diagnosed PID
in the United States at approximately 1 in 1,200 persons.
Conclusions: Diagnoses of PID in the United States are far
more common than suggested in the literature.
Keywords Primary immunodeficiency diseases . incidence .
prevalence in the United States
Introduction
Primary immunodeficiency diseases (PID) represent a class
of disorders in which there is an intrinsic defect in the
human immune system (rather than immune disorders that
are secondary to infection, chemotherapy or some other
external agent). In some cases, the body fails to produce
any or enough antibodies to fight infection. In other cases,
the cellular defenses against infection fail to work properly.
There are more than 150 different PID currently recognized
by the World Health Organization [1].
Although PID are often described as rare disorders, the
true incidence or population prevalence of these diseases,
either individually or in the aggregate, are not known be-
cause there is no screening for these defects at birth or at
any time during life anywhere in the world. The major
health surveys conducted by the government in the United
States, the National Health Interview Survey, and the
National Health and Nutrition Examination Survey do not
collect information on PID. No comprehensive population
survey has even been undertaken by the federal government
to estimate the incidence, prevalence or population char-
acteristics of these diseases in the United States. Hence,
although these diseases are clinically described in the
medical literature, and there have been some estimates of
the incidence and prevalence of some disorders based on
primary immunodeficiency registries in various countries,
[2–28] there are no data based on population screening of
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either the incidence or prevalence of these conditions in the
United States.
The objectives of the survey reported here were to (1)
estimate the population prevalence of PID in the United States
based on community samples rather than clinical samples,
using a national probability sampling frame so that population
size can be estimated, and (2) compare the characteristics of a
true national sample of PID patients to previous surveys of
patients within the Immune Deficiency Foundation.
Methods
A telephone survey was conducted with adult informants in
a national random digit dialing (RDD) sample of 10,005
households. The sample size was selected to detect the
lowest expected prevalence rate for diagnosed PID in the
United States. This was based on the results of the First
Immune Deficiency Foundation (IDF) National Patient Sur-
vey of medical specialists in 1995, which identified 1,502
doctors who reported following-up a total of 21,312 patients
with PID diagnoses. Because only 2,616 (15.0%) out of
17,451 specialists responded to the survey and only selected
specialists were covered by the sampling frame, these 21,312
cases should represent only a fraction of the total number
of diagnosed cases in the United States. However, if they
represented all diagnosed cases of PID in the United States
in 1995, then the population prevalence would be 0.8 cases
per 10,000 persons. Hence, a national sample of 10,000
households with an average of 2.7 persons per household
would be large enough to detect the lowest expected prev-
alence for diagnosed PID in the U.S. population.
The sample was geographically stratified by time zone.
The survey was conducted by experienced interviewers
using computer-assisted telephone interviewing (CATI)
from a central facility. Initial contact attempts were made
on evenings and weekends. Up to four follow-up contact
attempts were made to complete an interview. Interviews
were conducted between July 26 and August 25, 2005. A
cooperation rate (completes/completes+refusals) of 80%
was achieved.
An adult informant enumerated the adults and children
in the household. A total of 19,884 adults and 6,773 children
or 26,657 persons were reported in these households. This
provides a denominator for estimates of the prevalence of
PID among adults and children in these households. If there
were children in the household, respondents were asked if
any of the children had a chronic or serious health condition
and, if so, what the condition was. All respondents were
asked: “Has anyone in your household ever been diagnosed
with a primary immunodeficiency disease, such as common
variable immunodeficiency, IgA deficiency, IgG subclass
deficiency or any other immunodeficiency? (This is not
acquired immunodeficiency—AIDS).” The question includ-
ed the three most common diagnoses of PID patients in the
Second IDF National Survey of Patients in 2002, which
represented approximately three quarters of those in that
survey. If the respondents in the household surveyed
answered “yes”, they were asked the number of persons in
the household with a primary immunodeficiency, their age,
gender, and specific type of primary immunodeficiency. A
No, 96.2%
Not sure, 2.5%
Yes, 1.3%
Fig. 1 The reported presence of PID among 10,005 households.
Table 1 Non-PID Diagnoses
Diagnosis Percent
Lupus/SLE 13.0
Fibromyalgia 7.2
Autoimmune disease 5.1
Diabetes 5.1
Rheumatoid arthritis 4.1
Arthritis not spec 4.1
Multiple sclerosis 4.1
Crohns disease 4.1
AIDS 2.0
Cancer 2.0
ITP 2.0
Hashimoto’s 2.0
PMR 2.0
Anemia 1.0
Antiphospholipid 1.0
Sarcoidosis 1.0
Celiac disease 1.0
CREST 1.0
EBV 1.0
HPV 1.0
Leukemia 1.0
PSC 1.0
Reynauds 1.0
Sjogrens 1.0
Transplant 1.0
Trigiminal neuralgia 1.0
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limited set of additional questions were asked about treament
and contact.
Results
A total of 342 (10%) out of 3,478 households with children
aged 17 years old or younger reported that 1 or more children
in the household had a serious or chronic health condition.
Out of 6,773 children in these households, 4 were reported
to have an immunodeficiency disease. However, in response
to a follow-up question about the specific diagnosis, one of
these cases had been diagnosed with ITP, an autoimmune
disorder. The other three children were reported to have
diagnoses that are PID: agammaglobulinemia, selective IgA
deficiency, and IgG subclass deficiency.
All household informants were then asked: “Has anyone
in your household ever been diagnosed with a primary
immunodeficiency disease, such as common variable
immunodeficiency, IgA deficiency, IgG subclass deficiency
or any other immunodeficiency? (This is not acquired
immunodeficiency—AIDS).” In 131 (1.3%) out of 10,005
households surveyed, the household informant reported that
someone in the household had been diagnosed with a PID
(Fig. 1). However, when asked the specific diagnosis for
the condition, most (66%) reported a diagnosis other than a
primary immunodeficiency (Table 1). In many of these
cases, the diagnosed condition was either an autoimmune
disease or one that had an immunological component. Half
of the remaining cases either had no diagnosis given (16%)
or the condition could not be classified from the description
(3%) (Fig. 2).
Nonetheless, a total of 23 household members in 18
households were reported with a specific diagnosis for PID
(CVID, IgA, IgG, XLA, SCID, CGD) (Fig. 3). These
findings suggest a population prevalence of diagnosed PID
at 1 in 1,200 persons in the United States. This translates
into a population rate for diagnosed PID of 0.0863%. When
applied to the U.S. population of 297,386,000 persons, this
gives an estimate of approximately 250,000 persons with
diagnosed PID in the United States. The confidence bounds
about this estimate at the 95% confidence level suggest
that the number of persons with the diagnoses of PID in
the United States will be between 152,000 and 361,000
(Table 2).
The population characteristics of this national probability
sample of persons diagnosed with PID can be compared
Non PID 
Diagnosis
66%
Diagnosis Not 
Given
15%
Unclassifiable
3%
PID Diagnosis
16%
Fig. 2 Total number of patients (146) reported to have PID, only 23
(16%) of whom had a recognizable diagnosis of PID.
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Fig. 3 Specific PID diagnoses
given.
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to two earlier large scale, nationally distributed but non-
probability surveys of patients conducted by the Immune
Deficiency Foundation in 1996–1997 (N=3,046) and 2002
(N=1,526). The first IDF survey of patients was distributed
through physicians and medical centers known to the Foun-
dation to be treating patients (First Patient Survey) [29].
The second IDF survey of patients was mailed to patients
on IDF’s mailing list who had not participated in the first
survey (Second Patient Survey) [30].
The proportion of males in the national probability sam-
ple (56%) is somewhat higher than in the first IDF survey
(48%) and the second IDF survey (42%). The proportion of
patients under 18 years of age in the national probability
sample (43%) falls between the proportion under 18 years
of age in the first IDF survey (40%) and the second IDF
survey (50%) (Fig. 4). In general, the age and gender dis-
tribution of the probability sample is consistent with the
characteristics of patients known to the foundation.
The current Clinical Care Guidelines for Patients with
Primary Immunodeficiency Diseases recommend treatment
with intravenous immunoglobulin (IVIG) for agammaglob-
ulinemia, common variable immunodeficiency, hyper IgM,
Wiskott–Aldrich, and severe combined immunodeficiency.
Specific antibody deficiency, which may be a part of IgG
subclass deficiency, is also indicated although IgG subclass
deficiency alone is not. The majority of the patients in the
probability sample (57%) have diagnoses for which IVIG
therapy is the standard of care. This is similar to the pro-
portion of patients in the second IDF survey with diagnoses
for which IVIG is the standard of care (65%). However,
only 22% of PID patients in the national household telephone
survey sample were currently being treated with IVIG
compared to 67% of PID patients in the second IDF survey.
Indeed, only 67% of patients with aggammaglobulinemia
and 13% of patients with common variable immunodefi-
ciency in the national probability sample were currently
being treated with IVIG (Fig. 5). Hence, the surveys suggest
that immune deficient patients known to the IDF, either
through referral by specialist or individual information-
seeking are more likely to be following the recommended
therapy for the condition than the average patient in the
general community.
The national telephone survey confirmed that, despite an
IDF mailing list of more than 10,000 diagnosed PID patients,
only 4 out of 18 households containing a total of 23 PID
patients in a national probability sample had ever heard
of the Foundation, and only 1 out of 18 received the IDF
newsletter. If the rate of 1 out of 18 households with a patient
receiving a newsletter is divided into the IDF newsletter
mailing list of 10,000, it yields an independent estimate
of 180,000 households with patients diagnosed with a PID.
40%
48%50%
42%43%
56%
0%
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40%
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Under 18 Male
1st Patient Survey 2nd Patient Survey Prevalence SurveyFig. 4 Patients with PID diagno-sis by age and by sex in the
current and previous IDF surveys.
Table 2 Population Estimates of PID: Based on Specific Diagnosis
Population estimates of PID
Survey estimate of prevalence 0.0863%
Confidence interval at 95% 0.0352%
Lower bounds of estimate 0.0510%
Upper bounds of estimate 0.1215%
Total US population 297,386,040
Estimated PID US population 256,588
Lower bounds PID US population 151,769
Upper bounds PID US population 361,408
500 J Clin Immunol (2007) 27:497–502
If this household estimate is converted to a population
estimate of 1.3 patients per household (23/18), then the
survey yields an independent national estimate of approxi-
mately 230,000 persons diagnosed with a PID.
Discussion
PID are far more common than previously estimated. The
survey suggests prevalence rates for diagnosed PID as 1 in
2,000 for children, 1 in 1,200 for all persons, and 1 in 600
households. The population prevalence for PID found
among children in this survey replicates earlier unpublished
findings from large scale community surveys. The popula-
tion prevalence found in the survey presented here would
yield a total population estimate of between 150,000 and
360,000 persons in the United States diagnosed with PID.
Population characteristics of PID patients in the national
survey (age, gender) are similar to those in previous patient
surveys conducted by IDF. The distribution of PID patients
by diagnosis for which IVIG is the current standard of care
is similar for the national probability survey (57%) and the
most recent patient survey (65%). However, current use of
IVIG by PID patients in the national probability survey
(22%) was far lower than in previous IDF patient surveys
(67%), and the difference is statistically significant. If PID
patients in the general population used IVIG at the rates
used by patients in previous IDF surveys, there would be a
major increase in demand.
Neither the true incidence nor true prevalence of PID is
known. Whereas there have been estimates of these param-
eters from geographically limited studies [4, 8, 11, 13, 21,
26]; those estimates were based on diagnosed cases. The
number of undiagnosed cases is not known because there is
no population-based screening process for PID anywhere in
the world at any time during life. Underdiagnosis also occurs
because autopsies are rarely performed on infants or children
who die from infections. Moreover, as some individuals may
have less severe forms of primary immunodeficiency that
allow them to survive, they are often not diagnosed early in
life or at all.
Conclusions
In conclusion, these data suggest that PID are not rare. The
true incidence and prevalence of these conditions will never
be known until there is newborn or population screening for
these defects. Usually, the only way one knows that an
underlying immunodeficiency exists is that the patient
develops recurrent or serious infections and is then tested
for these defects. These patients appear outwardly normal
in most cases so that their appearances usually do not
trigger a suspicion of immunodeficiency. Occasionally, the
diagnosis is made before infections set in when there is a
family history of such defects and family members are
screened. Blood banks also often test both donors and
recipients for IgA deficiency because that condition is often
accompanied by the production of antibodies to IgA, which
can cause transfusions reactions. In one such blood bank
survey, the incidence was 1:333 putatively normal blood
donors [7]. The current study suggests that these conditions
are sufficiently common that primary care physicians are
likely to see patients with underlying primary immunode-
ficiency disorders in their practice and should test for these
disorders in patients with recurring, unusual or serious
22%
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67%
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Fig. 5 Current and past uses of
IVIG according to the type of
PID in the current survey.
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infections. In the absence of routine screening, physician
awareness of the relative frequency of these disorders is
critical to early diagnosis and treatment.
Acknowledgement The survey was conducted for the Immune
Deficiency Foundation, a nonprofit patient organization, through the
generous support of a grant from Talecris Biotherapeutics.
References
1. Notarangelo L, Casanova JL, Conley ME, Chapel ME, Fischer A,
Puck J et al. Primary immunodeficiency diseases: an update from
the International Union of Immunological Societies Primary
Immunodeficiency Diseases Classification Committee Meeting
in Budapest, 2005. J Allergy Clin Immunol 2006;117:883–96.
2. Ryser O, Morell A, Hitzig WH. Primary immunodeficiencies in
Switzerland: first report of the national registry in adults and
children. J Clin Immunol 1988;8:479–85.
3. Mila J, Matamoros N, Pons de Ves J, Raga S, Iglesias Alzueta J.
[The Spanish Registry of primary immunodeficiencies. REDIP-
1998]. Sangre (Barc) 1999;44:163–7.
4. Golan H, Dalal I, Garty BZ, Schlesinger M, Levy J, Handzel Z
et al. The incidence of primary immunodeficiency syndromes in
Israel. Isr Med Assoc J 2002;4:868–71.
5. Aghamohammadi A, Moein M, Farhoudi A, Pourpak Z, Rezaei N,
Abolmaali K et al. Primary immunodeficiency in Iran: first report
of the national registry of PID in children and adults. J Clin
Immunol 2002;22:375–80.
6. Affentranger P, Morell A, Spath P, Seger R. Registry of primary
immunodeficiencies in Switzerland. Immunodeficiency 1993;4:193–5.
7. Clark JA, Callicoat PA, Brenner NA. Selective IgA deficiency in
blood donors. Am J Clin Pathol 1983;80:210–3.
8. Fasth A. Immunodeficiency in children in Sweden (1974–1983).
J Clin Immunol 1982;2:86–92.
9. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multi-
institutional survey of the Wiskott–Aldrich syndrome. J Pediatr
1994;125:876–85.
10. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J,
Gaillin JI et al. Chronic granulomatous disease. Report on a
national registry of 368 patients. Medicine (Baltimore) 2000;79:
155–69.
11. Lim DL, Thong BY, Ho SY, Shek LP, Lou J, Leong K et al. Primary
immunodeficiency diseases in Singapore—the last 11 years. Singap
Med J 2003;44:579–86.
12. Montoya CJ, Henao J, Salgado H, Olivares MM, Lopez JA, Rugeles
C et al. [Phenotypic diagnosis of primary immunodeficiencies in
Antioquia, Colombia, 1994–2002]. Biomedica 2002;22:510–8.
13. Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immu-
nodeficiency diseases in Norway. J Clin Immunol 2000;20:477–85.
14. Javier FC III, Moore CM, Sorensen RU. Distribution of primary
immunodeficiency diseases diagnosed in a pediatric tertiary hos-
pital. Ann Allergy Asthma Immun 2000;84:25–30.
15. Zelazko M, Carneiro-Sampaio M, Cornejo de Luigi M, Garcia de
Olarte D, Porras Madrigal O, Berron Perez R et al. Primary
immunodeficiency diseases in Latin America: first report from
eight countries participating in the LAGID. Latin American Group
for Primary Immunodeficiency Diseases. J Clin Immunol
1998;18:161–6.
16. Eley BS, Hughes J, Cooper M, Pienaar S, Beatty DW. Primary
immunodeficiency diseases at Red Cross War Memorial Chil-
dren’s Hospital. S Afr Med J 1997;87:1684–8.
17. Bejaoui M, Barbouche MR, Sassi A, Larguche B, Miladi N,
Bouguerra A et al. [Primary immunodeficiency in Tunisia: study
of 152 cases]. Arch Pediatr 1997;4:827–31.
18. Baumgart KW, Britton WJ, Kemp A, French M, Roberton D. The
spectrum of primary immunodeficiency disorders in Australia.
J Allergy Clin Immunol 1997;100:415–23.
19. Grumach AS, Duarte AJ, Bellinati-Pires R, Pastorino AC, Jacob
CM, Diogo CL et al. Brazilian report on primary immunodefi-
ciencies in children: 166 cases studied over a follow-up time of
15 years. J Clin Immunol 1997;17:340–5.
20. Matamoros FN, Mila LJ, Espanol BT, Raga BS, Fontan CG.
Primary immunodeficiency syndrome in Spain: first report of the
national registry in children and adults. J Clin Immunol 1997;17:
333–9.
21. Nunez RM. Primary immunodeficiency in Colombian children.
Allergol Immunopathol (Madr) 1988;16:273–5.
22. Bernatowska E, Madalinski K, Michalkiewicz J, Gregorek H.
Primary immunodeficiency diseases in children treated in the
Children’s Memorial Hospital, Poland. Immunol Invest 1988;17:
107–20.
23. Datta U, Kumar L, Mehta S, Walia BN, Sharma BK, Sehgal S et al.
Primary immunodeficiency defects seen in PGI—one year study.
J Assoc Phys India 1984;32:701–04.
24. Luzi G, Businco L, Aiuti F. Primary immunodeficiency syn-
dromes in Italy: a report of the national register in children and
adults. J Clin Immunol 1983;3:316–20.
25. Luzi G, Businco L, Aiuti F. A national registry for primary
immunodeficiency syndromes in Italy: a report for the period
1972–1982. Birth Defects Orig Artic Ser 1983;19:161–3.
26. Hayakawa H, Iwata T, Yata J, Kobayashi N. Primary immunode-
ficiency syndrome in Japan. I. Overview of a nationwide survey
on primary immunodeficiency syndrome. J Clin Immunol 1981;1:
31–9.
27. Leiva LE, Zelazco M, Oleastro M, Carneiro-Sampaio M,
Condino-Neto A, Costa-Carvalho BT et al. Primary immunode-
ficiency diseases in Latin America: the second report of the
LAGID registry. J Clin Immunol 2007;27:101–8.
28. Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M,
Gharagozlu M et al. Frequency and clinical manifestations of
patients with primary immunodeficiency disorders in Iran: update
from the Iranian Primary Immunodeficiency Registry. J Clin
Immunol 2006;26:519–32.
29. Immune Deficiency Foundation. Primary immune deficiency
diseases in America: the first national survey of patients and
specialists. 1999 http://www.primaryimmune.org/pubs/IDF_survey_
complete.pdf
30. Immune Deficiency Foundation. Primary immune deficiency
diseases in America: the second national survey of patients and
specialists. 2003 http://www.primaryimmune.org/pubs/IDF_survey_
complete.pdf
502 J Clin Immunol (2007) 27:497–502
